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Correspondence Inhibition of Neointimal HyperplasiaWith a Novel Tacrolimus-Eluting SutureTo the Editor: Intimal hyperplasia surrounding the suture line
remains the leading cause of graft failure after coronary artery
bypass graft surgery and peripheral vascular bypass surgery.
Immunosuppressive drugs, such as tacrolimus, have been shown
to inhibit the development of intimal hyperplasia (1,2). We
have developed a novel drug-eluting suture coated with tacroli-
mus (DE-suture). The purpose of the present study performed
on a porcine model was to determine the efficacy of the new
suture coated with tacrolimus in preventing intimal hyperplasia.
The surface of a 7-0 polyvinylidene difluoride (PVDF) suture
was coated with tacrolimus using a bioabsorbable polymer for
controlled release of the drug. The porcine models used for the
suture experiments were randomized into the following 3 groups:
the control group (n  6), in which noncoated sutures were used;
the low-dose DE-suture group (n  6), in which low-dose (0.13
weight percent) tacrolimus-coated sutures were used; and the
high-dose DE-suture group (n  6), in which high-dose (0.40
weight percent) tacrolimus-coated sutures were used.
The femoral artery was dissected free from the anesthetized
animals. After proximal and distal cross-clamping, half-transverse
arteriotomy was performed in the femoral artery, followed by
interrupted suturing. Four weeks after implantation, femoral
arteries were harvested. The paraffin-embedded arterial speci-
mens were stained with hematoxylin-eosin and immunostained
using an alpha-smooth muscle actin antibody and a factor VIII
antibody to evaluate the degree of intimal hyperplasia and re-
endothelialization at the anastomotic site. To characterize neointimal
hyperplasia, the ratio of intimal thickness at the suture versus
nonsuture sites was calculated.
In regard to the arterial wall morphology, the nonsutured
reference site on the arterial wall including the neointimal area
showed no intimal hyperplasia. The control group showed signif-
icant neointimal hyperplasia at the suture site (the ratio of intimal
thickness at the suture/nonsuture sites: 23.0  5.0), whereas the
ow- and high-dose DE-suture groups showed significant reduc-
ion of the neointimal thickness (to 11.0 4.3 and 8.3  3.3; p 
.05) versus control (Figs. 1A to 1C and 1J). However, there was
no difference in the intimal thickness ratio at the suture/nonsuture
sites between the low- and high-dose DE-suture groups. The
neointima at the suture site contained the smooth muscle cells
(SMC) in all groups (Figs. 1D to 1F).
Histological analyses demonstrated a significantly less pro-
nounced medial inflammatory response and adventitial fibrosis in
both the DE-suture groups as compared with that in the control
group (p  0.05). In all groups, the arterial lumen was lined by
endothelial cells (EC) showing positive immunohistochemical
staining for factor VIII, which is an important factor for vascular
healing (Figs. 1G to 1I).
Tacrolimus (FK506, Asellas Pharma Inc., Tokyo, Japan) was
discovered in 1984 from the fermentation broth of a Japanese soilsample on Mt. Tsukuba that contained the bacterium Streptomyces
tsukubaensis. The drug is a macrolide immunosuppressant. It
inhibits several steps of the cascade of events leading to neointimal
formation and inhibits the proliferation of SMC. Previous exper-
imental data suggest that inhibition of cell cycle progression and
neointimal hyperplasia with tacrolimus may be an effective strategy
to prevent anastomotic stenosis. We considered that tacrolimus
may allow better re-endothelialization (1,2).
Intimal hyperplasia surrounding the suture line remains the
leading cause of graft failure. The main cause is invasion and
proliferation of SMC. Mechanical artery injury and the foreign
body effects of a suture, or viral response to the prosthesis, incite
acute and chronic inflammation in the vessel wall, with elaboration
of cytokines and growth factors that induce multiple signaling
pathways that activate SMC migration and proliferation. While
significant neointimal hyperplasia was observed at the suture site in
the control group, significant reduction of the neointimal area was
observed in the low- and high-dose DE-suture groups. In addi-
tion, the arterial lumen was lined in all groups by EC showing
positive immunohistochemical staining for factor VIII, an impor-
tant factor for vascular healing. According to the report by Matter
et al. (3), tacrolimus induces less injury of EC proliferation.
Recently, numerous drug-eluting devices have been developed
to prevent neointimal hyperplasia (2,4,5). They have been reported
to have the effect of preventing neointimal hyperplasia from the
adventitial site. Our new device is a simple advance to prevent
neointimal hyperplasia at the anastomotic suture site, as it allows
slow release of tacrolimus using a bioabsorbable polymer directly
into all layers of the blood vessel wall, including the intima, media,
and adventitia.
The results of our study in a porcine model demonstrate that the
DE-sutures inhibited neointimal hyperplasia at the anastomotic
suture site, and also inhibited the inflammatory response and
granulation tissue formation in the porcine model. Thus, this novel
suture may be useful in both coronary artery bypass graft surgery
and peripheral vascular bypass surgery.
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Differences in Cardiac
Resynchronization Therapy
Defibrillator Effectiveness
Between Men and Women
in the MADIT-CRT Trial
In a recent issue of the Journal, Arshad et al. (1) reported a
significantly greater reduction in death and heart failure withwomen than in men. In their discussion, they described the
characteristics of the patients. We wish to analyze these data more
in depth. The study population shows a difference between the
overall percentage of men and women, but in our opinion it is
worth noting a difference in the etiology of heart failure between
sexes. Over the last decades the prevalence of ischemic heart
disease has been demonstrated to be similar in both sexes with
increasing age (2), whereas in this study the majority of women
(72%) had nonischemic heart disease, as compared with only 36%
of men with nonischemic heart disease. Baseline functional and
structural parameters of left ventricular function are comparable
between the 2 groups. In general, patients with ischemic heart
disease have a worse prognosis (3,4), and coronary artery disease isw-dose
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